AU Patent

AU2023403208A1 — Modulation of syngap1 gene transcription using antisense oligonucleotides targeting regulatory rnas

Assigned to Camp4 Therapeutics Corp · Expires 2025-06-19 · 1y expired

What this patent protects

Described herein are methods of modulating SYNGAP1 gene transcription using antisense oligonucleotides (ASOs) targeting regulatory RNAs, such as promoter-associated RNAs, enhancer RNAs, and natural antisense transcripts (NATs). These methods are useful for increasing expression o…

USPTO Abstract

Described herein are methods of modulating SYNGAP1 gene transcription using antisense oligonucleotides (ASOs) targeting regulatory RNAs, such as promoter-associated RNAs, enhancer RNAs, and natural antisense transcripts (NATs). These methods are useful for increasing expression of SYNGAP1 mRNA and protein, thereby treating diseases associated with SYNGAP1 mutations.

Drugs covered by this patent

Patent Metadata

Patent number
AU2023403208A1
Jurisdiction
AU
Classification
—
Expires
2025-06-19
Drug substance claim
No
Drug product claim
No
Assignee
Camp4 Therapeutics Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.